Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tuky

Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like

Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay A

AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In

Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Co

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and S

Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and

Pharmaceutical Executive Daily: Peptide Ruling Stalls

Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded p

A Leadership Call to Action for Biotech

In this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta, The Vanguard Network

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup c

Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca m

Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima

FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Na

Pharmaceutical Executive Daily: FDA Approves Onswik

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks

Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the

Pharmaceutical Executive Daily: Nine European Drugmakers Note Concern Over Region's Pharma Investments

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and

Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic

Pharmaceutical Executive Daily: FDA Approves Fayuvi

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz

Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Or

Pharmaceutical Executive Daily: Novo Partners with Anthropic

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reim

Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why

Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie